 effect high-dos mcnu therapi hematopoiet stem cell treatment childhood acut leukemia/lymphoma high-risk featur clinic pharmacokinet studi toxic methyl mcnu drug conjunct peripher blood stem cell autograft pbsct children acut leukemia lymphoma high-risk featur earli phase studi mcnu cytosin arabinosid ara-c cyclophosphamid CY mg/kg busulfan mg/kg acut toxic high-dos therapi dose-limit factor regimen signific revers interstiti pneumon IP subsequ trial mcvac regimen dose mcnu risk IP studi progress clinic respons fifteen children aliv unmaintain complet remiss CR median follow-up period month rang month transplant mcnu-bas regimen total bodi irradi tbi import children seriou sequela irradi result clinic trial effect mcvac regimen pbsct